1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737-746.
2.
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-1177.
3.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019; 37: 2974-2986.
4.
Chi KN, Agarwal N, Bjartell A, et al. TITAN investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019; 381: 13-24.
5.
Smith MR, Hussain M, Saad F, et al. ARASENS trial investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022; 386: 1132-1142.
6.
Taha HF, Elsayed DH, Salem R, et al. Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. Contemp Oncol (Pozn) 2022; 26: 196-203.
7.
Bratt O, Carlsson S, Fransson P, et al. Swedish National Prostate Cancer Guidelines Group. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol 2022; 56: 278-284.
8.
Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol 2021; 79: 263-282.
9.
Nieder C, Stanisavljevic L, Dalhaug A, Haukland E. Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting. Scand J Urol 2022; 56: 114-118.
10.
Van Soest RJ, Efstathiou JA, Sternberg CN, Tombal B. The natural history and outcome predictors of metastatic castration-resistant prostate cancer. Eur Urol Focus 2016; 2: 480-487.
11.
Shore ND, Drake CG, Lin DW, et al. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. Prostate 2020; 80: 1159-1176.
12.
Iannantuono GM, Chandran E, Floudas CS, et al. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of clinical trials. Cancer Treat Rev 2023; 120: 102623.
13.
Patell K, Kurian M, Garcia JA, et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther 2023; 23: 731-744.
14.
Nieder C, Dalhaug A, Haukland E. Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting. Scand J Urol 2020; 54: 110-114.
15.
Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016; 17: 243-256. Erratum in: Lancet Oncol 2016; 17: e46.
16.
Tannock IF, de Wit R, Berry WR, et al. TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
17.
Fernando M, Anton A, Weickhardt A, et al. Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: analysis of an Australian real-world cohort. J Geriatr Oncol 2023; 14: 101621.
18.
Chowdhury S, Bjartell A, Lumen N, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: The Prostate Cancer Registry. Target Oncol 2020; 15: 301-315.
19.
Swami U, Aggarwal H, Zhou M, et al. Treatment patterns, clinical outcomes, health care resource utilization and costs in older patients with metastatic castration-resistant prostate cancer in the United States: An analysis of SEER-Medicare data. Clin Genitourin Cancer 2023; 21: 517-529.
20.
Thurin NH, Rouyer M, Jové J, et al. Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database. Expert Rev Clin Pharmacol 2022; 15: 1139-1145.
21.
Bhatia S, Landier W, Paskett ED, et al. Rural-urban disparities in cancer outcomes: opportunities for future research. J Natl Cancer Inst 2022; 114: 940-952.
22.
Weaver KE, Palmer N, Lu L, et al. Rural-urban differences in health behaviors and implications for health status among US cancer survivors. Cancer Causes Control 2013; 24: 1481-1490.
23.
Vigneswaran HT, Warnqvist A, Andersson TML, et al. Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scand J Urol 2021: 1-8.
24.
Yanagisawa T, Kawada T, Rajwa P, et al. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: a systematic review and meta-analysis. Urol Oncol 2023; 41: 177-191.
25.
Chi KN, Kheoh T, Ryan CJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration- resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol 2016; 27: 454-460.
26.
Pinart M, Kunath F, Lieb V, et al. German Prostate Cancer Consortium (DPKK). Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review. World J Urol 2020; 38: 613-635.
